[ET Net News Agency, 27 January 2022] CSPC Pharmaceutical Group Limited (01093) said
JMT601 (CPO107), a first-in-class drug candidate developed by the group, has been granted
Fast Track Designation by the U.S. Food and Drug Administration (FDA) for the treatment of
adult patients with relapsed or refractory diffuse large B-cell lymphoma.
Currently a multicentre, first-in-human, dose escalation and dose expansion Phase 1/2
clinical trial is underway in the U.S. to evaluate the safety, pharmacokinetics and
preliminary efficacy of JMT601 (CPO107) in the treatment of patients with advanced
Non-Hodgkin's lymphoma (NHL), including diffuse large B-cell lymphoma as a subpopulation.
(RC)